OPUS GENETICS INC. -

Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degeneration 2024 Conference

05 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

24 Jan 2024 15:10:00 By Nasdaq GlobeNewswire

Ocuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of Phentolamine Ophthalmic Solution for the Treatment of Decreased Visual Acuity under Dim (mesopic) Light Conditions

04 Jan 2024 07:00:01 By Nasdaq GlobeNewswire

Ocuphire Pharma Announces Presentation at Ophthalmology Innovation Summit (OIS) XIII

30 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

27 Nov 2023 15:38:14 By Nasdaq GlobeNewswire

Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer

27 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Ocuphire Pharma Announces Financial Results for Third Quarter 2023 and Provides Corporate Update

13 Nov 2023 07:00:01 By Nasdaq GlobeNewswire

Ocuphire Pharma Announces Successful End-of-Phase 2 Meeting with FDA for Oral APX3330 in Diabetic Retinopathy

02 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

01 Nov 2023 15:52:46 By Nasdaq GlobeNewswire

Ocuphire Pharma Announces Appointment of George Magrath, M.D., M.B.A., M.S., as Chief Executive Officer and Director

01 Nov 2023 07:05:00 By Nasdaq GlobeNewswire

Ocuphire Pharma to Present at AAO 2023 and Eyecelerator Retina Showcase

26 Oct 2023 07:00:01 By Nasdaq GlobeNewswire

Ocuphire Pharma to Present at Euretina and Retina Society Conferences in October

06 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Ocuphire Pharma and Viatris Announce FDA Approval of RYZUMVI™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g., Tropicamide) Agents

27 Sep 2023 07:00:12 By Nasdaq GlobeNewswire

Ocuphire Pharma to Participate in Three Upcoming Investment Bank Conferences

11 Sep 2023 08:41:55 By Nasdaq GlobeNewswire

Ocuphire Pharma to Present at ESCRS 2023 and MODLive! Conferences in September

07 Sep 2023 08:00:00 By Nasdaq GlobeNewswire

Abstract on ZETA-1 Study of APX3330 Receives Award at Women in Ophthalmology (WIO) Summer Symposium

28 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Ocuphire Pharma Announces Financial Results for Second Quarter 2023 and Provides Corporate Update

11 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Ocuphire Pharma to Present at the Canaccord 43rd Annual Growth Conference and the H.C. Wainwright Ophthalmology Conference in August

08 Aug 2023 07:00:01 By Nasdaq GlobeNewswire

Ocuphire to Present at American Society of Retina Specialists Annual Meeting and OIS Retina Innovation Summit

26 Jul 2023 07:00:01 By Nasdaq GlobeNewswire

Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

10 Jul 2023 16:19:14 By Nasdaq GlobeNewswire